Table 1.
Clinicopathological characteristics and treatment outcomes according to survival status in Nasopharyngeal Carcinoma.
| Characteristics | Total n=431 | Alive 364(84.5%) | Dead 67(15.5%) | p-value |
|---|---|---|---|---|
| Patient Characteristics | ||||
| Age (Median)@ | 48 (16–94) | 48 (16–94) | 45 (19–71) | 0.542 |
| Age Groups | ||||
| <40 Years | 148 (34.3) | 126 (34.6) | 22 (32.8) | 0.889 |
| ≥40 Years | 283 (65.7) | 238 (65.4) | 45 (67.2) | |
| Gender | ||||
| Female | 139 (32.3) | 119 (32.7) | 20 (29.9) | 0.776 |
| Male | 292 (67.7) | 245 (67.3) | 47 (70.1) | |
| Stage Group | ||||
| Stage I | 4 (0.9) | 3 (0.8) | 1 (1.5) | 0.107 |
| Stage II | 35 (8.1) | 33 (9.1) | 2 (3.0) | |
| Stage III | 101 (23.4) | 90 (24.7) | 11 (16.4) | |
| Stage IV | 291 (67.5) | 238 (65.4) | 53 (79.1) | |
| Nodal Stage | ||||
| N0 | 40 (9.3) | 32 (8.8) | 8 (11.9) | 0.195 |
| N1 | 71 (16.5) | 61 (16.8) | 10 (14.9) | |
| N2 | 179 (41.5) | 158 (43.4) | 21 (31.3) | |
| N3 | 141 (32.7) | 113 (31.0) | 28 (41.8) | |
| Treatment Variables | ||||
| Planning Technique | ||||
| 3DCRT/Conventional | 143 (33.2) | 118 (32.4) | 25 (37.3) | 0.481 |
| IMRT/Rapid Arc | 288 (66.8) | 246 (67.6) | 42 (62.7) | |
| Radiotherapy Dose | ||||
| ≥65 Gy | 412 (95.6) | 351 (96.4) | 61 (91.0) | 0.095 |
| <65 Gy | 19 (4.4) | 13 (3.6) | 6 (9.0) | |
| Chemotherapy Setting | ||||
| Induction | 412 (95.6) | 349 (95.9) | 63 (94.0) | 0.191 |
| Adjuvant | 8 (1.9) | 5 (1.4) | 3 (4.5) | |
| No chemotherapy | 11 (2.6) | 10 (2.7) | 1 (1.5) | |
| Concurrent Chemotherapy with RT | ||||
| Yes | 391 (90.7) | 336 (92.3) | 55 (82.1) | 0.019* |
| No | 40 (9.3) | 28 (7.7) | 12 (17.9) | |
| Outcomes | ||||
| Treatment Response | ||||
| Complete | 307 (71.2) | 269 (73.9) | 38 (56.7) | <0.008** |
| Other (partial/stable/progression) | 124 (28.8) | 95 (26.1) | 29 (43.3) | |
| Recurrence | ||||
| Yes | 143 (33.2) | 90 (24.7) | 53 (79.1) | <0.001** |
| No | 288 (66.8) | 274 (75.3) | 14 (20.9) | |
| Site of Recurrence (n=143) | ||||
| Local | 70 (49.0) | 45 (50.0) | 25 (47.2) | 0.863 |
| Distant | 73 (51.0) | 45 (50.0) | 28 (52.8) | |
| Palliative Chemotherapy (n=184) | ||||
| Yes | 80 (43.5) | 49 (36.6) | 31 (62.0) | 0.003** |
| No | 104 (56.5) | 85 (63.4) | 19 (38.0) | |
| Recurrence Free Survival | ||||
| > 5 years | 125 (29) | 122 (33.5) | 03 (4) | <0.001** |
| ≤ 5 years | 306 (71) | 242 (66.5) | 64 (96) | |
| Survival | ||||
| > 5 years | 184 (42.7) | 175 (48) | 09 (13) | <0.001** |
| ≤ 5 years | 247 (57.3) | 189 (52) | 58 (87) |
Table 2.
Univariate and Multivariate Analysis of Prognostic Factors for Overall Survival in Nasopharyngeal Carcinoma.
| Factors | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| HR [95% CI] | P-value | HR [95% CI] | P-value | ||
| Gender | Female | Ref | - | 1.32(0.761–2.292) | 0.324 |
| Male | 1.176(0.695–1.989) | 0.545 | |||
| Age (Years) | Age <40 | Ref | - | 1.206(0.698–2.084) | 0.503 |
| Age ≥ 40 | 1.116(0.668–1.861) | 0.676 | |||
| Chemotherapy concurrent | Yes | 0.495(0.258–0.948) | 0.034* | 0.411(0.189–0.891) | 0.024* |
| No | Ref | - | |||
| Chemotherapy setting | Induction | Ref | - | 1 | |
| Adjuvant | 2.364 [0.740–7.556] | 0.147 | 1.196(0.323–4.431) | 0.789 | |
| No Chemo | 0.501(0.069–3.169) | 0.493 | 0.329(0.035–3.104) | 0.331 | |
| Stage | I, II | Ref | - | 6.984(1.541–31.657) | 0.021* |
| III, IV | 4.627 [1.129–18.961] | 0.033* | |||
| RT Dose | <65 Gy | 1.440(0.570–3.635) | 0.440 | 2.134(0.744–6.118) | 0.158 |
| ≥ 65 Gy | Ref | - | |||
| Planning Technique | 3D Conformal + Conventional | Ref | - | - | - |
| IMRT | 0.885(0.121–6.482) | 0.905 | 0.786(0.105–5.870) | 0.815 | |
| VMAT | 0.330(0.041–2.642) | 0.296 | 0.316(0.038–6.118) | 0.284 | |
Table 3.
Univariate and Multivariate Analysis of Prognostic Factors for Recurrence-free Survival in Nasopharyngeal Carcinoma
| Factors | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| HR [95% CI] | P-value | HR [95% CI] | P-value | ||
| Gender | Female | Ref | - | 1.175(0.812–1.701) | 0.392 |
| Male | 1.172(0.821–1.672) | 0.382 | |||
| Age (Years) | Age <40 | Ref | - | 1.554(1.065–2.267) | 0.022* |
| Age ≥ 40 | 1.346(0.943–1.922) | 0.102 | |||
| Chemotherapy concurrent | Yes | 0.870(0.492–1.540) | 0.663 | 0.553(0.296–1.034) | 0.063 |
| No | Ref | - | |||
| Chemotherapy | Induction | Ref | - | - | - |
| Adjuvant | 0.383(0.054–2.740) | 0.339 | 0.206(0.027–1.565) | 0.127 | |
| No Chemo | 0.209(0.029–1.496) | 0.119 | 0.104(0.013–0.831) | 0.033* | |
| Stage | I, II | Ref | 2.047(1.027–4.081) | 0.42 | |
| III, IV | 1.905(0.970–3.744) | 0.061 | |||
| RT Dose | <65 Gy | 2.713(1.464–5.027) | 0.002** | 4.372(2.288–8.352) | <0.001** |
| ≥ 65 Gy | Ref | ||||
| Planning Technique | 3D Conformal +Conventional | Ref | - | - | - |
| IMRT | 0.522(0.163–1.665) | 0.272 | 0.472(0.147–1.522) | 0.209 | |
| VMAT | 0.322(0.097–1.067) | 0.064 | 0.279(0.083–0.935) | 0.039* | |
Table 5.
Restricted Mean Survival Time and Median Follow-Up in Nasopharyngeal Carcinoma.
| Statistics | Overall (months) | Recurrence Free (Months) |
|---|---|---|
| Restricted Mean Survival Time | 176.43±11.51 (153.88–198.98) | 91.08±3.40 (84.42–97.74) |
| Median1 Follow-up | 61.0 (57.55–64.45) | 59.00 (56.56–61.44) |
Table 4.
Long-Term Overall and Recurrence-Free Survival Rates in Nasopharyngeal Carcinoma.
| Time Point | Survival Rate (%) (95% C.I) | |
|---|---|---|
| Overall | Recurrence Free | |
| 5- Year | 83.3 (79.3–87.4) | 63.2 (58.4–68.5) |
| 7-Year | 81.3 (76.9–86.0) | 55.6 (49.2–62.7) |
| 10-Year | 71.2 (61.7–82.2) | 55.6 (49.2–62.7) |

Figure 1.
Kaplan-Meier curve of overall survival according to clinical stage in nasopharyngeal carcinoma.

Figure 2.
Kaplan-Meier curve of recurrence-free survival according to clinical stage in nasopharyngeal carcinoma.